- For US Eye Care
Professionals - Important Safety
Information - Full Prescribing
Information - Patient
Information - Medical
Information - Visit
Patient Site - REQUEST A REP
- SIGN UP
Inhibit Inflammation
Hear from leading eye care professionals about why Xiidra is their clear choice for treating dry eye disease
Early Symptom Relief
See what leading eye care professionals have to say about the speed of onset their patients have experienced with Xiidra
Help Your Patients
Listen to leading eye care professionals discuss the benefits of Xiidra and how it feels to help patients find relief
Get Xiidra Samples
Login or register for Bausch + Lomb MySampleCloset® to request samples and receive additional information on Xiidra
Start here
videos
Educating Patients On Xiidra: Best Practices
Find out the top 6 things to discuss with a patient who is getting started on Xiidra
downloads
Xiidra Prior Authorization Checklist
Ensure seamless access assistance for appropriate patients with this easy-to-use checklist
Xiidra Sample Tier Exception Letter
Fill out this form to request a payer to cover Xiidra at a lower tier
Xiidra Sample Appeals Letter
Utilize this resource if a patient's insurance company denies coverage
Xiidra Letter of Medical Necessity (New Patient Start)
Use this template to request prior authorization or document medical necessity for treatment with Xiidra
Xiidra Letter of Medical Necessity (Patient Continuation)
Use this template to document medical necessity and request continuation of coverage for treatment with Xiidra
BlinkRx Guide
Download these step-by-step instructions on filling a prescription through BlinkRx
BlinkRx Fax Form
This form is used to e-prescribe Xiidra through BlinkRx. For more details, see the BlinkRx Guide
BlinkRx EHR Flashcard
This flashcard provides information on how to find BlinkRx in your electronic health record (EHR)
Xiidra Patient Brochure
This resource provides patients with a comprehensive overview of Xiidra
BlinkRx Quick Guide
(for Commercial Patients)
This resource is about the BlinkRx program for patients with commercial insurance
BlinkRx Quick Guide (for Government-Insured Patients)
This resource is about the BlinkRx program for patients with government insurance, including Medicare Part D
Xiidra Savings Card
Get patients started with the My Savings Program by having them register for a copay card or activate an existing card online
Xiidra is indicated for the treatment of signs and symptoms of dry eye disease.1
Across 5 clinical studies, the most common AEs (reported in 5%–25% of patients) were instillation-site irritation, dysgeusia, and reduced visual acuity.1
By targeting the ICAM-1/LFA-1 interaction, Xiidra blocks T-cell activation at multiple sites, inhibits T-cell migration to the ocular surface, and reduces the release of proinflammatory cytokines.1,2
Xiidra is used once in the morning and once in the evening, approximately 12 hours apart.1
Contact lenses should be removed before using Xiidra and may be put back in 15 minutes after using the treatment.1
Xiidra has ~90% overall coverage for commercial and Medicare Part D patients nationwide.* Find formulary coverage in your area by clicking here.
The cost for Xiidra will vary per patient. For patients who have limited or no prescription coverage, contact 1-877-4XiiDRA (1-877-494-4372) or visit www.patientassistance.bausch.com. For more on helping patients start and stay on Xiidra, and information on Xiidra's $0 Co-Pay Program for commercially eligible patients or the Insider Support Program, please call the Xiidra Access Program at 1-877-494-4372.
BlinkRx assists with prior authorizations, cost, and customer support, offering a seamless experience for your practice and patients. Find a helpful guide and additional downloadable resources about BlinkRx here.
There are a variety of ways to receive samples of Xiidra. You can visit and log in to Bausch + Lomb MySampleCloset®, call 1-800-746-1584, or use the “Request a Rep” button located in the main menu to connect with a representative.
Signs of dry eye inflammation can include conjunctival hyperemia, corneal and conjunctival staining, and tear hyperosmolarity.3 Symptoms of dry eye inflammation can include conjunctival redness and ocular pain, among others.4
AN INDUSTRY LEADER
Xiidra coverage exceeds Restasis® for both
commercial and Medicare Part D patients*
XIIDRA WAS WELL TOLERATED
Help patients get started by discussing AEs and the safety profile of Xiidra1,4
AE, adverse event; ICAM-1, intercellular adhesion molecule 1; LFA-1, lymphocyte function-associated antigen 1.
The exact mechanism of action of Xiidra in dry eye disease is not known.
Xiidra significantly reduced symptoms of eye dryness at 2 weeks (based on Eye Dryness Score compared to vehicle) in 2 of 4 studies, with improvements observed at 6 and 12 weeks in all 4 studies.1
*Based on MMIT data from March 2025. Up to 94% of commercial and 70% of Medicare Part D patients may be covered.
Indication and important safety information
Indication
Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).
Important Safety Information
- Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
- In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
- To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
- Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
- Safety and efficacy in pediatric patients below the age of 17 years have not been established.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for full Prescribing Information for Xiidra.
References
- Xiidra. Prescribing information. Bausch & Lomb Inc.
- Data on file. Bausch & Lomb Inc.
- Rao SK, Mohan R, Gokhale N, Matalia H, Mehta P. Inflammation and dry eye disease—where are we? Int J Ophthalmol. 2022;15(5):820-827. doi:10.18240/ijo.2022.05.20
- Donnenfeld ED, Karpecki PM, Majmudar PA, et al. Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study. Cornea. 2016;35(6):741-748. doi:10.1097/ICO.0000000000000803
Indication and important safety information
Indication
Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).
Important Safety Information
- Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
- In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.